FDA’s UDI Draft Guidance Aims to Help with Rule Compliance
FDA just released a draft guidance to assist with compliance with the Unique Device Identifier (UDI) rule. The UDI rule requires that most medical device labels and packages have a UDI that is easy to read and is in automatic identification and data capture technology (AIDC) forms. UDI’s are issued under a system run by FDA-accredited issuing agencies (IAs). The agency has currently accredited three IAs, which are located in New Jersey, Arizona and California.
The draft, Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI), clarifies the following for labelers and FDA-accredited IAs to aid in compliance with the UDI rule:
- Two forms of a UDI
- Content of the UDI (including data delimiters that identify specific data elements within the UDI)
- Order of data in a UDI and UDI carrier (the means to convey the UDI and any non-UDI elements in easily readable plain-text and AIDC forms)
FDA is accepting comments on the draft guidance for the next 60 days.
Related Articles
-
The agency has posted new education modules about the unique device identification rule.
-
The unique device identification rule is far more than just a labeling rule.
-
Are you UDI-ready? Get the facts to achieve compliance fast.
-
The FDA does not intend to enforce the GUDID submission requirements for Class I and unclassified devices, other than implantable, life-supporting or life-sustaining devices, regardless of whether they are consumer health products, before December 8, 2022.
